share_log

Aethlon Medical | 10-K/A: Annual report (Amendment)

Aethlon Medical | 10-K/A: Annual report (Amendment)

Aethlon Medical | 10-K/A：年度报表(修正版)
美股SEC公告 ·  2024/08/15 16:17

Moomoo AI 已提取核心信息

Aethlon Medical has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2024, primarily to include Part III information previously omitted. The amendment provides comprehensive details on director and executive compensation, corporate governance structures, and related party transactions.Key leadership changes include James B. Frakes serving as Interim CEO and CFO since November 2023, following the departure of former CEO Charles J. Fisher Jr. The company's board consists of five directors, with Edward G. Broenniman as Chairman. Executive compensation includes base salaries ranging from $390,000 to $500,000 for key officers, with additional equity-based incentives.The amendment also details the company's director compensation policy, which provides annual retainers and equity grants to non-employee directors. The filing includes updated information on beneficial ownership, with current directors and executive officers collectively holding approximately 1.0% of outstanding shares. The company maintains comprehensive indemnification agreements with its officers and directors.
Aethlon Medical has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2024, primarily to include Part III information previously omitted. The amendment provides comprehensive details on director and executive compensation, corporate governance structures, and related party transactions.Key leadership changes include James B. Frakes serving as Interim CEO and CFO since November 2023, following the departure of former CEO Charles J. Fisher Jr. The company's board consists of five directors, with Edward G. Broenniman as Chairman. Executive compensation includes base salaries ranging from $390,000 to $500,000 for key officers, with additional equity-based incentives.The amendment also details the company's director compensation policy, which provides annual retainers and equity grants to non-employee directors. The filing includes updated information on beneficial ownership, with current directors and executive officers collectively holding approximately 1.0% of outstanding shares. The company maintains comprehensive indemnification agreements with its officers and directors.
Aethlon Medical已提交截至2024年3月31日财年的10-K表格年报修改案第1号，主要是为了包含之前遗漏的第三部分信息。该修正案提供了关于董事和高管薪酬、公司治理结构以及关联交易的全面细节。关键的领导变更包括詹姆斯·B·弗雷克斯自2023年11月起担任临时首席执行官和首席财务官，接替前首席执行官查尔斯·J·费舍尔。公司的董事会由五位董事组成，爱德华·G·布罗恩尼曼担任主席。高管薪酬的基本工资范围从390,000美元到500,000美元不等，并提供额外的股权激励。该修正案还详细说明了公司的董事薪酬政策，为非员工董事提供年度薪酬和股权授予。提交的文件包括有关实益所有权的更新信息，目前的董事和高管共同持有大约1.0%的流通股。公司与其高管和董事保持全面的补偿协议。
Aethlon Medical已提交截至2024年3月31日财年的10-K表格年报修改案第1号，主要是为了包含之前遗漏的第三部分信息。该修正案提供了关于董事和高管薪酬、公司治理结构以及关联交易的全面细节。关键的领导变更包括詹姆斯·B·弗雷克斯自2023年11月起担任临时首席执行官和首席财务官，接替前首席执行官查尔斯·J·费舍尔。公司的董事会由五位董事组成，爱德华·G·布罗恩尼曼担任主席。高管薪酬的基本工资范围从390,000美元到500,000美元不等，并提供额外的股权激励。该修正案还详细说明了公司的董事薪酬政策，为非员工董事提供年度薪酬和股权授予。提交的文件包括有关实益所有权的更新信息，目前的董事和高管共同持有大约1.0%的流通股。公司与其高管和董事保持全面的补偿协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日